Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.
Saved in:
| Title: | Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection. |
|---|---|
| Authors: | Nations KR; Merck Sharp Dohme Corp., Whitehouse Station, NJ, USA., Bursi R, Dogterom P, Ereshefsky L, Gertsik L, Mant T, Schipper J |
| Source: | Drugs in R&D [Drugs R D] 2012 Sep 01; Vol. 12 (3), pp. 127-39. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100883647 Publication Model: Print Cited Medium: Internet ISSN: 1179-6901 (Electronic) Linking ISSN: 11745886 NLM ISO Abbreviation: Drugs R D Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
